Ena Hasimbegovic
Overview
Explore the profile of Ena Hasimbegovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han E, Muller-Zlabinger K, Hasimbegovic E, Poschenreithner L, Kastner N, Maleiner B, et al.
Biomolecules
. 2025 Feb;
15(2).
PMID: 40001603
Endothelial dysfunction mediated by elevated levels of autoantibodies against vasoactive peptides occurring after COVID-19 infection is proposed as a possible pathomechanism for orthostatic intolerance in long COVID patients. This case-control...
2.
Hamzaraj K, Han E, Hasimbegovic E, Poschenreiter L, Vavrikova A, Lukovic D, et al.
Vaccines (Basel)
. 2024 Jun;
12(6).
PMID: 38932339
Patients with long COVID syndrome present with various symptoms affecting multiple organs. Vaccination before or after SARS-CoV-2 infection appears to reduce the incidence of long COVID or at least limit...
3.
Gyongyosi M, Hasimbegovic E, Han E, Zlabinger K, Spannbauer A, Riesenhuber M, et al.
Biomedicines
. 2023 Dec;
11(12).
PMID: 38137533
Cardiac magnetic resonance (CMR) studies reported CMR abnormalities in patients with mild-moderate SARS-CoV-2 infection, suggesting ongoing myocardial inflammation. Patients ( = 278, 43 ± 13 years, 70.5% female) with post-acute...
4.
Mester-Tonczar J, Einzinger P, Hasimbegovic E, Kastner N, Schweiger V, Spannbauer A, et al.
Biomolecules
. 2023 Dec;
13(12).
PMID: 38136582
Despite the widespread use of doxorubicin (DOX) as a chemotherapeutic agent, its severe cumulative cardiotoxicity represents a significant limitation. While the liposomal encapsulation of doxorubicin (Myocet, MYO) reduces cardiotoxicity, it...
5.
Gyongyosi M, Lukovic D, Mester-Tonczar J, Zlabinger K, Einzinger P, Spannbauer A, et al.
NPJ Vaccines
. 2023 Sep;
8(1):145.
PMID: 37773184
Epstein-Barr virus (EBV) reactivation may be involved in long-COVID symptoms, but reactivation of other viruses as a factor has received less attention. Here we evaluated the reactivation of parvovirus-B19 and...
6.
Traxler D, Dannenberg V, Zlabinger K, Gugerell A, Mester-Tonczar J, Lukovic D, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445825
Small extracellular vesicles (EVs) and their cargo are an important component of cell-to-cell communication in cardiac disease. Allogeneic adipose derived stem cells (ADSCs) are thought to be a potential approach...
7.
Lukovic D, Hasimbegovic E, Winkler J, Mester-Tonczar J, Muller-Zlabinger K, Han E, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108624
We have designed translational animal models to investigate cardiac profibrotic gene signatures. Domestic pigs were treated with cardiotoxic drugs (doxorubicin, DOX, n = 5 or Myocet, MYO, n = 5)...
8.
Kovarik J, Bileck A, Hagn G, Meier-Menches S, Frey T, Kaempf A, et al.
iScience
. 2022 Dec;
26(1):105717.
PMID: 36507225
To investigate long COVID-19 syndrome (LCS) pathophysiology, we performed an exploratory study with blood plasma derived from three groups: 1) healthy vaccinated individuals without SARS-CoV-2 exposure; 2) asymptomatic recovered patients...
9.
Hasimbegovic E, Russo M, Andreas M, Werner P, Coti I, Wiedemann D, et al.
Front Cardiovasc Med
. 2022 Apr;
9:849972.
PMID: 35402525
Background: Congestion and plasma volume expansion are important features of heart failure, whose prognostic significance has been investigated in a range of surgical and non-surgical settings. The aim of this...
10.
Hasimbegovic E, Papp L, Grahovac M, Krajnc D, Poschner T, Hasan W, et al.
J Pers Med
. 2021 Nov;
11(11).
PMID: 34834414
Transcatheter aortic valve replacement (TAVR) has rapidly become a viable alternative to the conventional isolated surgical aortic valve replacement (iSAVR) for treating severe symptomatic aortic stenosis. However, data on younger...